Literature DB >> 15026312

Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome.

Anna Virginia Gulino1, Daniele Moratto, Silvano Sozzani, Patrizia Cavadini, Karel Otero, Laura Tassone, Luisa Imberti, Silvia Pirovano, Lucia D Notarangelo, Roberta Soresina, Evelina Mazzolari, David L Nelson, Luigi D Notarangelo, Raffaele Badolato.   

Abstract

The chemokine receptor CXCR4 and its functional ligand, CXCL12, are essential regulators of development and homeostasis of hematopoietic and lymphoid organs. Heterozygous truncating mutations in the CXCR4 intracellular tail cause a rare genetic disease known as WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis), whose pathophysiology remains unclear. We report CXCR4 function in 3 patients with WHIM syndrome carrying heterozygous truncating mutations of CXCR4. We show that CXCR4 gene mutations in WHIM patients do not affect cell surface expression of the chemokine receptor and its internalization upon stimulation with CXCL12. Moreover, no significant differences in calcium mobilization in response to CXCL12 are found. However, the chemotactic response of both polymorphonuclear cells and T lymphocytes in response to CXCL12 is increased. Furthermore, immunophenotypic analysis of circulating T and B lymphocytes reveals a decreased number of memory B cells and of naive T cells and an accumulation of effector memory T cells associated with a restricted T-cell repertoire. Based on our results, we suggest that the altered leukocyte response to CXCL12 may account for the pathologic retention of mature polymorphonuclear cells in the bone marrow (myelokathexis) and for an altered lymphocyte trafficking, which may cause the immunophenotyping abnormalities observed in WHIM patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026312     DOI: 10.1182/blood-2003-10-3532

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  65 in total

Review 1.  Regulation of neutrophil trafficking from the bone marrow.

Authors:  Ryan B Day; Daniel C Link
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

2.  WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4.

Authors:  Qian Liu; Haoqian Chen; Teresa Ojode; Xiangxi Gao; Sandra Anaya-O'Brien; Nicholas A Turner; Jean Ulrick; Rosamma DeCastro; Corin Kelly; Adela R Cardones; Stuart H Gold; Eugene I Hwang; Daniel S Wechsler; Harry L Malech; Philip M Murphy; David H McDermott
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

3.  WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.

Authors:  Toshinao Kawai; Uimook Choi; Lanise Cardwell; Suk See DeRavin; Nora Naumann; Narda L Whiting-Theobald; Gilda F Linton; Jaehyun Moon; Philip M Murphy; Harry L Malech
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

Review 4.  Wiskott-Aldrich syndrome: another piece in the puzzle.

Authors:  L D Notarangelo; L Mori
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 5.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

Review 6.  Immunity to microbes: lessons from primary immunodeficiencies.

Authors:  Magda Carneiro-Sampaio; Antonio Coutinho
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

7.  CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions.

Authors:  Kyle J Eash; Jacquelyn M Means; Douglas W White; Daniel C Link
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

Review 8.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

9.  A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

Authors:  David H McDermott; Qian Liu; Daniel Velez; Lizbeeth Lopez; Sandra Anaya-O'Brien; Jean Ulrick; Nana Kwatemaa; Judy Starling; Thomas A Fleisher; Debra A Long Priel; Melissa A Merideth; Robert L Giuntoli; Moses O Evbuomwan; Patricia Littel; Martha M Marquesen; Dianne Hilligoss; Rosamma DeCastro; George J Grimes; Samuel T Hwang; Stefania Pittaluga; Katherine R Calvo; Pamela Stratton; Edward W Cowen; Douglas B Kuhns; Harry L Malech; Philip M Murphy
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

10.  Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 "chemosynapse".

Authors:  Dayanidhi Raman; Nicole F Neel; Jiqing Sai; Raymond L Mernaugh; Amy-Joan L Ham; Ann J Richmond
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.